Wake-test latency is not extra sleep on 200 mg modafinil

MWT gains are not extra sleep hours

Trial sleep-latency gains do not repay sleep debt and do not open an airway. Residual OSA sleepiness still needs documented CPAP. This bench explains the Schedule IV tablet. It does not dispense it.

Why hormonal contraception needs a backup on Provigil

CYP3A4 induction can drop steroid contraceptive levels. Backup during therapy and for one month after stop is on the label, not optional counseling. Unexplained rash is a stop - Stevens-Johnson language is not marketing copy.

Schedule IV cash bands for 100 mg tablets

Labeled wake dose is often 200 mg; coupon tools still quote 100 mg × 30 for a price check. Amazon, Cost Plus, Target, Publix - August 2026 snapshots. ZIP moves the number. Script required.

Wake Hours Without Amphetamine PK

Label check: a 34-year-old on ethinyl estradiol gets pregnant on modafinil because the prior prescriber never mentioned enzyme induction. A CPAP download shows two hours nightly use while the patient insists modafinil fixed the apnea. A college health clinic fills Provigil for finals week with no sleep study. Those are the modafinil failures — not 'narcolepsy affects hundreds of thousands.'

Label check: excessive daytime sleepiness in clinic is meetings, near-misses, honest Epworth scores. Causes split into hypersomnia syndromes, fragmented sleep from apnea, circadian wreckage from night shifts. Modafinil belongs after diagnosis and after first-line fixes: sleep opportunity, CPAP for apnea, schedule work for shift workers.

Provigil got FDA approval December 1998 for narcolepsy; later OSA/hypopnea as adjunct to CPAP and shift work disorder. Label language is blunt: modafinil treats sleepiness, not apneic events. Stop CPAP because the pill feels good and you traded untreated airway for alertness.

Schedule IV in the U.S. Lower abuse potential than amphetamines at therapeutic doses — still not caffeine. Diversion happens. Match prescription to documented sleep disorder and PDMP rules where they apply.

Armodafinil is the R-enantiomer, longer half-life, separate label. This page is racemic modafinil — Provigil and AB generics. Off-label ADHD, cancer fatigue, cognitive enhancement lack the narcolepsy trial backbone.

Label check: primary care 'always tired' without polysomnography masks apnea, depression, hypothyroidism. Ask snoring, witnessed apneas, sedating meds before Schedule IV wake agents.

Commercial drivers, pilots, safety-sensitive jobs: valid Rx does not clear every employer policy. Occupational health may be stricter than DEA scheduling.

Modafinil at 200 mg daily nudges BP and HR modestly in normotensives. Severe hypertension, LVH, recent MI — label cautions still bind you.

Patient says modafinil 'does nothing' at 200 mg? Check morning timing, sedating co-meds, and whether they expected euphoria. Wakefulness without high is the design, not failure.

Label check: narcolepsy type 2 without cataplexy still gets wake therapy when MSLT confirms objective sleepiness — modafinil does not fix orexin-independent pathophysiology.

Idiopathic hypersomnia is variable; modafinil off-label. Solriamfetol or sodium oxybate may win in specialty centers after MSLT/MWT.

Formulary prior auth often wants sleep medicine sign-off — know your triggers before outpatient start.

Residents reflex dose-escalate to 400 mg when the real problem is CPAP leak at 3 AM. Fix the device before you fix the milligrams.

Histamine and Orexin Tone, Not a Stimulant Rush

The wake-promoting mechanism is not reducible to a single receptor. Modafinil inhibits the dopamine transporter (DAT), raising synaptic dopamine in nucleus accumbens and striatum, but with substantially lower affinity than cocaine or methylphenidate. DAT occupancy PET studies at clinical doses explain alertness without typical stimulant euphoria at labeled exposures.

Beyond dopamine, modafinil influences orexin/hypocretin pathways, histamine release from tuberomammillary neurons, and glutamatergic/GABAergic balance in hypothalamus and cortex. In narcolepsy type 1, orexin neuron loss removes endogenous wake drive; modafinil partially compensates pharmacologically but does not replace missing hypocretin.

Modafinil does not significantly promote norepinephrine release via reverse transport — the amphetamine mechanism responsible for many cardiovascular spikes. That distinction supports use in some cardiac-sensitive patients at standard doses, though individual tolerance varies.

Electroencephalography during wakefulness shows increased alpha and beta activity, consistent with cortical activation rather than reversal of a single sedative receptor. Modafinil is not a GABA antagonist and does not substitute for treating sedative overdose.

Cataplexy in narcolepsy requires separate management — sodium oxybate, antidepressants with anticataplectic properties, or newer agents. Modafinil improves wakefulness scores without reliably suppressing cataplexy episodes.

Solriamfetol and pitolisant offer alternative mechanisms when modafinil is insufficient or poorly tolerated. Mechanism diversity in hypersomnia treatment reflects incomplete understanding of modafinil's full CNS site profile.

Label check: students often ask whether modafinil is 'just a weak stimulant.' The fair answer: overlapping wake circuits, different binding profile and abuse liability assessment, and distinct interaction pattern via CYP induction.

Label check: histamine H3 inverse agonists and orexin receptor agonists represent newer targets that may displace modafinil in some hypersomnia subtypes over the coming decade — current labeling remains the prescribing standard.

Modafinil in traumatic brain injury fatigue shows mixed trial results; post-concussive sleep dysfunction often responds better to sleep schedule rehabilitation before pharmacologic wake promotion.

EEG beta activity increases do not correlate linearly with subjective alertness — patients may object to 'nothing happening' while MWT improves objectively.

Morning Peak and the CYP3A4 Induction Clock

Oral modafinil is well absorbed with peak plasma concentrations at two to four hours. Food delays Tmax modestly without meaningfully reducing total exposure — unlike sildenafil, strict fasting is not required for consistent effect.

Elimination half-life is approximately twelve to fifteen hours in healthy adults, supporting once-daily morning dosing. Evening doses predictably cause insomnia; patients who take a missed morning dose at noon and cannot sleep should not repeat that mistake.

Hepatic metabolism proceeds via amide hydrolysis and CYP3A4-mediated pathways to inactive modafinil acid and modafinil sulfone. No active metabolite contributes clinically relevant wake promotion.

Chronic modafinil induces CYP3A4, CYP2B6, and CYP1A2. The induction is bidirectionally important: modafinil levels may fall over weeks while co-administered substrates (oral contraceptives, cyclosporine, some antivirals) lose exposure. Labeling mandates backup contraception during therapy and for one month after discontinuation based on ethinyl estradiol clearance data.

Severe hepatic impairment approximately doubles AUC; dose reduction to 100 mg daily is recommended. Geriatric patients may need lower doses when hepatic or cardiac comorbidity limits tolerance, though formal geriatric PK studies show only modest age-related clearance changes.

Renal impairment does not require routine dose adjustment because elimination is primarily hepatic, but metabolite accumulation in end-stage renal disease has limited study — use caution and monitor for prolonged side effects.

Less than ten percent of unchanged drug appears in urine; hemodialysis does not meaningfully remove parent modafinil. Overdose management is supportive; no antidote exists.

Label check: auto-induction after multi-week exposure may reduce modafinil's own levels — loss of effect after months of stable dosing warrants adherence review before automatic dose escalation.

MWT Latency Gains That Still Leave Sleep Debt

Narcolepsy registration trials demonstrated significant improvement in Maintenance of Wakefulness Test (MWT) sleep latency and Clinical Global Impression of Change versus placebo over nine to twelve weeks at 200 mg daily. Effect sizes are moderate — this is symptomatic therapy, not disease modification.

Obstructive sleep apnea studies enrolled patients with documented CPAP use and residual sleepiness. Modafinil reduced Epworth Sleepiness Scale scores as adjunct therapy without changing apnea-hypopnea index. CPAP adherence must be verified before attributing persistent sleepiness to a need for pharmacologic adjunct.

Shift work disorder trials dosed 200 mg approximately one hour before the start of the night shift, improving wakefulness during work hours. Commute safety after shift end requires counseling as drug effects wane — modafinil does not eliminate sleep debt.

Dose-ranging data support 200 mg over 400 mg for most patients; higher total daily doses increase headache and anxiety without proportional benefit in registration analyses. Split dosing is rarely necessary.

Open-label extensions suggest sustained benefit in responders without classical tachyphylaxis over one to two years, though loss of effect often reflects worsening sleep disorder, new sedating medications, or CYP induction lowering modafinil exposure rather than receptor downregulation.

MWT provides objective wakefulness measurement distinct from subjective Epworth scores — both appear in labeling and guideline discussions. Patients can feel subjectively improved while MWT remains below normal thresholds.

Modafinil does not replace sodium oxybate for cataplexy and nocturnal sleep fragmentation in narcolepsy type 1. Comprehensive narcolepsy management often combines wake promotion with anticataplectic therapy.

200 mg in the Morning, Not a Nightcap

Standard dose for narcolepsy and OSA adjunct: 200 mg once daily in the morning. Administering after noon invites insomnia; there is no PRN indication for labeled uses.

Shift work disorder: 200 mg approximately one hour before the start of the work shift, not at wake-up on a day off. Rotating shift workers need individualized schedules rather than copying day-shift narcolepsy prescriptions.

Severe hepatic impairment (Child-Pugh class C or equivalent clinical judgment): 100 mg daily maximum per labeling. Monitor for prolonged side effects.

Missed dose: skip if late in the day; do not double the next morning dose. Accumulation from double dosing increases headache and anxiety without improving next-day alertness proportionally.

400 mg total daily dose divided was studied but rarely justified given adverse effect burden. If 200 mg fails after adequate sleep disorder treatment optimization, specialist referral precedes reflex dose doubling.

Armodafinil 150 mg is not milligram-equivalent to modafinil 200 mg — switching enantiomer products requires retitration and label consultation, not automatic substitution.

Discontinuation after chronic use rarely requires taper at 200 mg daily, unlike high-dose stimulants, though rebound sleepiness for several days is common. Plan return-to-work timing accordingly.

Hormonal Contraception Needs a Backup Method

CYP3A4 induction is the headline interaction. Oral contraceptives, cyclosporine, midazolam, some HIV protease inhibitors, and many chemotherapeutic agents may lose efficacy. Document backup contraception and monitor transplant drug levels when modafinil starts or stops.

Label check: cYP3A4 inhibitors such as ketoconazole increase modafinil exposure; watch for dose-limiting headache and insomnia. CYP2C19 substrates (phenytoin, diazepam, omeprazole) may show altered levels bidirectionally — phenytoin levels deserve monitoring when modafinil is added.

Concurrent CNS stimulants (amphetamine, methylphenidate) add sympathomimetic load without additive wake benefit proven in primary care populations. Combination is specialist territory for refractory hypersomnia.

Alcohol tolerance may decrease; patients report enhanced sedative effects of alcohol while on modafinil despite subjective alertness — counsel against assuming they are safe to drive after combined use.

Label check: rifampin and carbamazepine as CYP inducers may lower modafinil levels, reducing efficacy. St John's wort carries similar theoretical risk.

Label check: cyclosporine level reduction via CYP3A4 induction has caused graft rejection in published case reports — transplant teams must be notified before modafinil initiation.

Warfarin shows modest interaction potential via CYP induction; INR monitoring after start and stop is prudent in anticoagulated patients.

Ethinyl estradiol is the headline, but any CYP3A4 substrate on the med list deserves a second look at modafinil start and stop — contraception failures are the ones that make headlines.

Patient on modafinil asks for 'something stronger' — amphetamine co-prescription is specialist territory; sympathomimetic load without proven additive wake benefit in primary care.

Unexplained Rash Stops the Tablet That Day

Label check: headache, nausea, nervousness, insomnia, and anxiety are common dose-related effects. Earlier morning dosing and dose reduction to 100 mg often resolve insomnia without abandoning therapy.

Label check: serious rash including Stevens-Johnson syndrome and multi-organ hypersensitivity (DRESS) prompted FDA warnings. Discontinue modafinil at the first sign of rash unless a clinician is certain of non-drug etiology — viral exanthems in children and modafinil rash can be difficult to distinguish retrospectively.

Psychiatric symptoms — depression exacerbation, mania, hallucinations — require monitoring, especially with prior mood disorder history. Modafinil is not antidepressant therapy despite off-label fatigue use in depression.

Cardiovascular: modest blood pressure and heart rate increases possible. Use caution in uncontrolled hypertension, significant left ventricular hypertrophy, and recent myocardial infarction per labeling.

Pregnancy registry data remain limited. Modafinil reduces hormonal contraceptive efficacy — unintended pregnancy risk is a counseling priority for women of childbearing potential.

Pediatric use is not FDA-approved; serious rash reports in juvenile populations support restricting pediatric prescribing to specialist protocols with informed consent.

Stevens-Johnson syndrome risk, though low in absolute terms, carries high morbidity — the label's rash warning is not boilerplate.

Pregnancy, Hepatic Load, and Shift-Work Limits

Pregnancy: insufficient human data for confident risk-benefit in mild sleepiness; severe narcolepsy may justify use after specialist discussion. Contraception counseling is mandatory regardless of pregnancy intent because of enzyme induction.

Lactation: limited data; consider alternative wake strategies when breastfeeding if symptoms permit.

Geriatric: start 100 mg if hepatic impairment, polypharmacy, or cardiac disease present. Fall risk from insomnia if dosed late.

OSA populations: confirm CPAP adherence with device download or partner report before labeling residual sleepiness as modafinil-indication. Weight loss and positional therapy remain foundational.

Shift workers: address light hygiene, sleep environment, and strategic napping — modafinil supports alertness during shift but does not fix circadian misalignment alone.

Hepatic cirrhosis: 100 mg daily cap; avoid in decompensated disease unless benefit clearly outweighs exposure uncertainty.

Document CPAP Before You Call It Residual Sleepiness

Baseline: document sleep disorder diagnosis, CPAP adherence for OSA, Epworth or MWT if available, blood pressure, concomitant CYP3A4 substrates, and contraception plan.

Follow-up: reassess sleepiness scales at four to eight weeks, review new medications (especially antibiotics and antifungals affecting CYP), and repeat contraception counseling at every visit.

Counsel patients that modafinil promotes wakefulness, not cognitive enhancement beyond normal rested baseline in healthy volunteers — expectation management reduces perceived treatment failure.

Driving: improved simulator performance in sleep-deprived volunteers does not override jurisdiction-specific impaired driving laws. Patients should not drive when subjectively impaired regardless of prescription status.

Report rash, mouth sores, fever, or lymphadenopathy immediately — hold modafinil until evaluated.

Occupational policies may require disclosure; provide documentation of diagnosis and treatment for employer medical review when requested.

Sleep clinic follow-up at 4–8 weeks: Epworth, new sedating meds, contraception still in place, CPAP hours if OSA.

Document MWT if disability or CMV certification pending — subjective 'I feel fine' rarely suffices.

Alcohol: patients report lower tolerance while feeling alert — not safe to drive because the Rx is in their pocket.

Sleep Disorder Integration and Device Therapy

Polysomnography before modafinil for unexplained sleepiness documents apnea-hypopnea index, periodic limb movements, and REM sleep without atonia suggesting REM behavior disorder masquerading as daytime sleepiness.

Split-night CPAP titration in newly diagnosed OSA should complete before labeling residual sleepiness as modafinil-indication — leak, mask fit, and adherence data from device download trump patient self-report.

Shift work disorder management includes timed light exposure, melatonin timing for day sleep, and bedroom darkening — modafinil supports alertness during night shift but does not replace circadian hygiene.

MWT sleep latency below eight minutes at baseline in narcolepsy trials defines excessive sleepiness entry criteria — repeat testing after modafinil initiation documents objective response for disability documentation.

Epworth Sleepiness Scale subjective scores may improve disproportionately to MWT in some patients — both have roles in follow-up.

Multiple sleep latency test should not be performed while patient is on modafinil — washout one to two weeks per protocol before diagnostic retesting if diagnosis uncertain.

Jet lag and travel-related sleepiness are not labeled indications — caffeine and melatonin remain first-line before off-label modafinil for short trips.

Pediatric narcolepsy management in specialty centers sometimes uses modafinil off-label after stimulant trials — rash risk mandates higher vigilance than in adults.

Schedule IV Paperwork Before the First Fill

Document sleep diagnosis on chart and Rx — narcolepsy, OSA with CPAP adherence note, or shift work disorder with schedule.

Screen CYP3A4 substrates at start and stop: OCP, patch, ring, cyclosporine, midazolam, some HIV regimens.

Morning 200 mg standard; 100 mg if Child-Pugh C. Shift work: ~1 h before night shift, not wake-up on days off.

Prior auth: attach sleep study, CPAP compliance printout, or specialist letter.

Schedule IV — valid Rx, state PDMP if applicable, no 'as needed for studying.'

Armodafinil switch is retitration, not mg-for-mg substitution.

Floor Cases Where Fatigue Was Not Narcolepsy

OSA patient feels great on modafinil, CPAP download shows 90 minutes nightly — you treated alertness, not apnea. Pull the wake agent conversation until adherence is fixed or document why adjunct is still appropriate with cardiology/sleep co-sign.

Woman on norgestimate/ethinyl estradiol starts modafinil for shift work — backup contraception or non-hormonal IUD. Label is explicit: one month backup after stop. This is not theoretical; clearance data drove the warning.

Transplant patient on cyclosporine; modafinil started for fatigue. Graft rejection case reports exist from CYP3A4 induction. Notify transplant team before first fill, not after level crash.

Label check: rash day nine — hold modafinil, photograph lesions, admit if mucosal involvement. 'Probably viral' is how SJS gets missed.

Label check: night shift nurse takes 200 mg at 7 AM on flip week to stay awake for day shift — insomnia, then requests higher dose. Timing must match work block, not narcolepsy morning default.

MWT improved, Epworth still high — patient feels subjectively unchanged. Both metrics matter for disability paperwork and expectation setting.

Label check: loss of effect after six stable months: check new rifampin, St John's wort, auto-induction, and adherence before jumping to 400 mg.

College health Provigil for exams — redirect to sleep hygiene; Schedule IV without diagnosis is diversion setup.

Cataplexy present, only modafinil prescribed — wake improved, falls unchanged. Add anticataplectic therapy; modafinil is half the narcolepsy plan.

Label check: ritonavir-boosted antiretroviral plus modafinil — net interaction direction messy; expect insomnia and level surprises either way.

Post-TBI fatigue trial mixed — sleep schedule rehab before pharmacologic wake promotion.

Employer drug screen negative for amphetamines — patient assumes no disclosure needed. Occupational policy may still require sleep specialist letter.

Pregnancy planned: stop modafinil, confirm contraception off induction window, registry if severe narcolepsy forces continuation.

Generic color change triggers nocebo stop — AB-rated generic is appropriate; review timing and dose before brand-only refill.

Psychiatric mania on modafinil in bipolar patient — discontinue, treat mood episode, avoid rechallenge without psych co-management.

What Sleep Clinic Gets Wrong on Provigil

If a truck driver asks for modafinil for highway hypnosis without sleep study, that is a red flag — diagnose before prescribing Schedule IV wake agents.

Epworth score above 10 despite CPAP download showing four hours nightly use is adherence problem first, modafinil second.

Label check: ritonavir co-therapy for HIV raises modafinil levels — watch insomnia headache though induction direction net effect varies.

Modafinil acid inactive metabolite accumulates in renal failure without wake benefit — hepatic clearance still primary.

Night shift nurses who take modafinil at 3 AM for 7 AM day shift on flip week get insomnia — timing must match actual work block.

Label check: college students requesting Provigil for exams without narcolepsy diagnosis need sleep hygiene counseling not stimulant prescription.

DRESS multi-organ hypersensitivity rare but reported — fever eosinophilia organ dysfunction after modafinil start warrants stop.

Oral contraceptive patch and ring also CYP3A4 substrates — backup methods apply not just pills.

Modafinil does not treat cataplexy — sodium oxybate pitolisant or venlafaxine anticataplectic strategies when needed.

Post-TBI fatigue trials mixed — rehabilitation sleep schedule before pharmacologic wake promotion.

Generic tablet color change triggers nocebo discontinuation — counsel that AB-rated generic is appropriate.

Modafinil washout two weeks before repeat MSLT if diagnostic clarity needed.

Heart rate increase five to ten beats at 200 mg usually clinically silent — still avoid in recent MI per label.

Psychiatric mania activation in bipolar patient on modafinil — discontinue and treat mood episode.

Occupational health may ban modafinil in safety-sensitive roles despite valid Rx — employer policy not DEA schedule alone.

Split-night CPAP study pending — do not start modafinil for OSA until PAP trial completes and adherence measured.

MWT for disability claim — washout modafinil 1–2 weeks before retesting if diagnostic clarity needed.

Solriamfetol switch when modafinil insufficient — sleep medicine referral, not primary care dose chase to 400 mg.

DRESS rare — fever, eosinophilia, organ dysfunction after start warrants stop and workup.

Oral contraceptive patch and vaginal ring — same CYP3A4 induction as pills; backup methods apply.

Histamine and orexin pathways partial explanation — cataplexy still needs separate agent in type 1 narcolepsy.

Post-TBI clinic requests wake agent — rehab sleep schedule first; mixed trial data for modafinil in concussion fatigue.

Insurance armodafinil step edit — retitrate, document side effects; not automatic equivalent swap.

Telehealth sleep follow-up: ask CPAP hours from device app screenshot — self-report overestimates use.

Ward and Sleep Clinic Notes

Hospital consult 'fatigue' on oncology ward — rule delirium, anemia, opioids before modafinil; not outpatient narcolepsy pathway.

Discharge on modafinil from sleep clinic — ensure PCP knows contraception counseling was done; many fall through crack.

Night float pages for insomnia after modafinil given at 2 PM on wrong shift — timing education at every fill.

Psychiatry co-manage when modafinil considered in MDD fatigue — not antidepressant; mania risk in bipolar.

Epworth drop 6 points, still sleeps driving — subjective improvement ≠ safe driving; counsel jurisdiction laws.

Generic modafinil AB-rated — patient insists brand only; review adherence and timing before prior auth battle.

Pediatric narcolepsy off-label — rash vigilance higher than adults; specialist center only.

Caffeine 600 mg plus modafinil — anxiety without linear wake benefit; cut caffeine before raising modafinil.

Cyclosporine level check two weeks after modafinil start in transplant — document in chart even if stable.

Shift worker pregnant — modafinil pregnancy data limited; occupational safety plus OB plus sleep medicine triangle.

MWT Card Before You Sign the CIV

Label check: tell every woman of childbearing potential: modafinil induces CYP3A4 — hormonal contraception needs backup during therapy and for one month after the last dose. Patch and ring count too.

OSA patients: show them the CPAP download. Modafinil is adjunct to airway treatment, not a substitute. If they feel better and use CPAP less, that conversation happens now.

Rash, mouth sores, fever, lymph nodes — stop modafinil and call. Do not finish the bottle to see if it fades.

Shift workers: dose one hour before the work block, not at breakfast on a day off. Rotating schedules need individualized timing — copy-paste narcolepsy sigs fail.

Morning 200 mg; 100 mg in severe hepatic impairment. Missed afternoon dose — skip it; do not double tomorrow.

Expect wakefulness, not euphoria. MWT may improve before the patient feels subjectively fixed — that is normal, not underdosing.

Before steroids or transplant immunosuppression in sleepy patients — think sleep diagnosis first; modafinil never belongs on the 'fatigue' problem list without a sleep workup.